SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community anticipates potential impacts from a new ETF, with many expressing bullish sentiment and speculating on price targets. Some traders are suggesting a potential integration with X could boost the crypto, while others highlight Dogecoin's scarcity relative to the US dollar as a long-term advantage.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the stock experiences a significant rally, with community members discussing potential price targets and the strength of the current upward momentum. Some traders point to technical indicators suggesting an overbought condition and anticipate a pullback, while others highlight Elon Musk's influence and potential catalysts for further gains. News regarding Tesla's energy business and a new lawsuit alleging discriminatory hiring practices are also circulating among investors.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

The crypto $WAGMI.X is trending as community members rally around its long-term potential and strong community. Many are rolling profits into $WAGMI.X, touting its strong presence on the Solana blockchain and its connection to the $PUMP.X ecosystem. The community sentiment is overwhelmingly positive, with many expressing conviction for its future.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. ($ASST) is trending as the merger with Strive Enterprises Inc. has been completed, and the company raised $750M with potential for $1.5B via warrants. The community is discussing the potential for a short squeeze, particularly with the borrow fee at extremely high levels, as well as the impact of the new CUSIP number. Many are speculating on significant upward price movement in the coming days.

Apu, also known as Peepo or Helper, is a pepe-variant that is used to represent a much younger, kinder and more naive anthropomorphic frog. Fed up with low-effort memecoins, more often than not led by deceptive developers, Apu decided to create his own fairly launched, fully transparent coin: $APU – the one and only coin for all frens.

Apu Apustaja 

Apu Apustaja ($APU.X) is trending as community members highlight its strong community, 4chan roots, and association with popular meme culture; some are drawing comparisons to other memecoins like $PEPE.X and $HONK.X. Traders are also discussing its recent listing on Hyperliquid, marking its entrance as the first memecoin from Murad's list to bridge directly from Ethereum to Hyperliquid.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recently announced $20 million investment agreement, sparking discussions about the company's future and potential for a short squeeze. The community is closely watching upcoming events, with some anticipating significant price movement. Others are wary of potential dilution and volatility given the low float.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as discussions emerge around potential links between COVID vaccines and child deaths following reports of administration plans to address the issue, creating community concern and uncertainty. Community members are debating the validity of the data, potential liabilities, and future impact on the stock, while also discussing Pfizer's broader portfolio beyond COVID vaccines, including cancer drugs, and its attractiveness as a dividend stock. The stock's performance is being scrutinized amid wider debates about vaccine mandates and the role of government in healthcare.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending as investors anticipate new hyperscaler deals, fueled by excitement following NBIS's recent partnership with Microsoft. The community is closely monitoring upcoming events like the key vote and potential ETF launch, with some anticipating a short squeeze amidst growing AI infrastructure demand. Bullish sentiment is high as the stock approaches previous highs.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks ($ANET) is trending due to positive analyst ratings and price target increases, driven by its strong position in AI-driven networking and data center infrastructure. Community discussions revolve around the stock's recent price action, with some seeing a buying opportunity amid profit-taking, while others express frustration over market manipulation. $ANET's growth potential in the expanding AI networking market remains a key talking point.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

GDX is trending due to gold's continued strength and potential for further gains, with some arguing it represents a compelling hedge against economic uncertainty. Community discussions revolve around whether gold miners are undervalued and poised to outperform gold itself. Broader market context includes factors like inflation, interest rate policies, and geopolitical tensions that are all impacting the sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +100.00% and +2.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of CytomX Therapeutics hit their highest levels in nearly two months on Monday after the company&nbsp;posted better-than-expected first-quarter earnings and revealed promising early trial results for its lead oncology candidate.CytomX posted quarterly earnings per share of $0.27, which surpassed analyst estimates of $0.13.&nbsp;Its revenue climbed to $50.92 million, also beating analyst estimates of $35.42 million.CytomX shares surged by 129.4% on Monday, reaching $2.13.The company revealed early Phase 1 trial results showing positive outcomes for CX-2051, an EpCAM-directed Probody antibody-drug conjugate targeting late-line colorectal cancer (CRC).The CTMX-2051-101 Phase 1 study provided these results after beginning the trial in April 2024.&nbsp;The clinical research on April 7 included 25 patients with metastatic CRC who received CX-2051 treatment through seven different dose levels during three-week intervals.Among the 18 patients receiving therapeutic doses of the CX-2051 treatment, 28% reached confirmed partial response according to RECIST v1.1 standards, which surpasses the standard response rates of low to mid-single digits associated with third-line or later colorectal cancer treatments.&nbsp;Patients on CX-2051 received 10 mg/kg, where three out of seven achieved confirmed partial responses.&nbsp;The Disease Control Rate (DCR) reached 94% across these doses while the median progression-free survival stood at 5.8 months.&nbsp;Ten patients stayed on study treatment at the point of data cutoff out of 18 participants.CEO Sean McCarthy, D.Phil., expressed his optimism about the results while confirming that CX-2051 continues to be the company's number one strategic focus.&nbsp;McCarthy said that the findings establish EpCAM as a valuable target in cancer treatment and enable CX-2051 to advance into CRC applications and various other EpCAM-expressing cancer types.The current dose expansion phase will lead CytomX to start a Phase 2 study in early 2026.Additionally, CytomX priced its 76.9 million share secondary offering at $1.30 per share.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 4,567% increase in 24-hour message volume.One user expressed confidence that the stock could reach $3.50 the following day.&nbsp;<stembedurl>https://stocktwits.com/LittleWhiteBall/message/614390932</stembedurl>Another noted the rarity of a stock rising after a company issues a secondary offering at a significantly lower price.<stembedurl>https://stocktwits.com/engrman1/message/614387241</stembedurl>The stock has risen 100.9% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CytomX Stock Hits 2-Month High After Upbeat Q1 Earnings, Promising Early Data For Cancer Drug

The company shared Phase 1 trial results for CX-2051, an antibody-drug conjugate for advanced colorectal cancer, with 28% of patients achieving confirmed partial responses.

Equity

Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates

Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates PR Newswire...

Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection

Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection PR Newswire VANCOUVER, BC, May...

Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer

Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed...

What's Going On With CytomX Stock?

CytomX Therapeutics shares are racing higher Wednesday. The company said it will report first-quarter results and provide an initial CX-904 Phase 1a dose escalation update on May 8, after the close...

HC Wainwright Comments on CytomX Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:CTMX)

CytomX Therapeutics, Inc. (NASDAQ:CTMX  Free Report)  Research analysts at HC Wainwright issued their FY2025 EPS estimates for CytomX Therapeutics in a report released on Monday...

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the...

CytomX Therapeutics announces milestone achievement in PROBODY TCB

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

CytomX Therapeutics Announces Milestone Achievement in PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX - - Program is one of several ongoing collaboration...

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CTMX
CytomX Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CTMX News

CTMX CytomX Therapeutics Inc